| Therapeutic | Spartalizumab |
| Target | PDCD1 |
| Heavy Chain | EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (Feb '25) | Phase-II |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2017 |
| INN Year Recommended | 2018 |
| Companies Involved | Asan Medical Center, Dana-Farber Cancer Institute, Novartis, Novartis Oncology, Palobiofarma, Seoul National University Hospital |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma, Breast cancer, Colorectal cancer, Diffuse large B cell lymphoma, Gastric cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Solid tumours, Acute myeloid leukaemia, Cancer, Liver cancer, Lymphoma, Multiple myeloma, Myelodysplastic syndromes, Ovarian cancer, Pancreatic cancer, Renal cancer |
| Conditions Discontinued | Neuroendocrine tumours |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
